Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that HIV specialists desire antiretrovirals with greater efficacy in highly treatment experienced patients and with better long-term viral suppression. Products from new classes, such as the integrase inhibitors, could address some of these needs, but according to survey findings, they face some high hurdles imposed by current products such as Gilead/BMS's Atripla when it comes to penetrating the broader HIV market. Merck's MK-0518 (in combination with two nucleoside reverse transcriptase inhibitors) could become the future gold standard therapy if preliminary data is substantiated in larger, ongoing studies.
"MK-0518 offers a novel mechanism of action and appears highly potent in both treatment-naive and highly treatment experienced patients," said Sylvia Eash, Ph.D., an analyst at Decision Resources. "Clinical studies to date demonstrate that MK-0518 is also a relatively safe and well-tolerated antiretroviral. Among MK-0518's advantages is that it will be highly active against HIV strains resistant to current drugs."
The report entitled HIV: Turning Physician Insight into Projected Patient Share also found that a high proportion of HIV specialists will initially use the novel classes (integrase and CCR5 inhibitors) as add-ons to current regimens instead of replacing a protease inhibitor or non-nucleoside reverse transcriptase inhibitor. Furthermore, physicians believe that Prezista (recently launched by Tibotec, a Johnson & Johnson subsidiary) will mainly compete with Abbott's Kaletra and Boehringer Ingelheim's Aptivus -- both of which are used in treatment-experienced patients.
About HIV: Turning Physician Insight into Projected Patient Share
HIV: Turning Physician Insight into Projected Patient Share covers the current and future state of the HIV drug market. The report includes:
- More than 3,000 physician responses that define drug attributes that drive prescription now and in the future. - Clinical end point tradeoffs that are most influential to physicians. - Areas of unmet need with highest potential. - Benchmark trial results for specific drug opportunities. - Patient share potential for emerging therapies and target product profiles. - Decision Resources proprietary analysis of commercial factors that accelerate or constrain a drug's market potential. - Promotion: DTC spend, detailing intensity. - Reimbursement: formulary tier, prior approval restriction, quantity limits. - Labeling: black box warnings, approved patient segments, contraindications. - Competition: order of entry, pricing, generic entry, pipeline sales forecast. - Medical practice: decision trees, treating physician type, line of therapy. - Comparisons of the key clinical attributes of current and emerging therapies in the areas of efficacy, safety, and delivery. - Analysis and supporting data that identifies the clinical "Gold Standard" now and over the next ten years. - Key insights as to which clinical end points have the greatest influence on physician decision-making.
The report can be purchased by contacting Decision Resources. Members of the media may request a complimentary copy or an interview with an analyst.
About Decision Resources
Decision Resources, Inc., (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders. For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
First Call Analyst:
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, or firstname.lastname@example.org
Web site: http://www.decisionresources.com/